Cepheid Releases Improved Test For BCR-ABL

Cepheid has released its improved Xpert BCR-ABL Monitor test, to be marketed as a CE IVD product under the European Directive. It is intended to aid European clinicians in the monitoring of patients with Chronic Myelogenous Leukemia (CML).

John Bishop, CEO of Cepheid, said: The GeneXpert System is capable of producing unheard of sensitivity levels for a molecular system – a potential key benefit in monitoring minimal residual disease.”

Similar to our recently announced test for Mycobacterium tuberculosis, Xpert BCR-ABL Monitor uses nested PCR, a critical amplification process possible only within a fully closed integrated molecular sample prep/test system. We will continue to extend the many unique benefits of the GeneXpert System across multiple markets and testing applications, he added.